22nd Century Group Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de 22nd Century Group han disminuido a una tasa media anual de -38.8%, mientras que en la industria Tobacco los beneficios crecieron en un 9.7% anualmente. Los ingresos han ido creciendo a una tasa media de 21% al año.

Información clave

-38.8%

Tasa de crecimiento de los beneficios

-22.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Tobacco	18.1%
Tasa de crecimiento de los ingresos	21.0%
Rentabilidad financiera	n/a
Margen neto	-296.8%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Market Participants Recognise 22nd Century Group, Inc.'s (NASDAQ:XXII) Revenues Pushing Shares 1,233% Higher

Apr 02

Time To Worry? Analysts Just Downgraded Their 22nd Century Group, Inc. (NASDAQ:XXII) Outlook

Aug 20

With 22nd Century Group, Inc. (NASDAQ:XXII) It Looks Like You'll Get What You Pay For

Jun 14

Does 22nd Century Group (NASDAQ:XXII) Have A Healthy Balance Sheet?

Jan 13

22nd Century adds Creager as distribution partner for its VLN cigarettes in Colorado

Oct 03

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero 22nd Century Group. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:XXII Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	22	-65	31	3
30 Sep 23	84	-139	54	7
30 Jun 23	84	-78	57	7
31 Mar 23	75	-69	51	7
31 Dec 22	28	-37	32	4
30 Sep 22	49	-47	39	5
30 Jun 22	39	-44	31	5
31 Mar 22	30	-36	28	4
31 Dec 21	31	-33	26	4
30 Sep 21	23	-25	23	4
30 Jun 21	25	-20	19	4
31 Mar 21	28	-21	17	4
31 Dec 20	28	-20	15	4
30 Sep 20	28	-20	13	4
30 Jun 20	27	-26	14	6
31 Mar 20	27	-29	13	7
31 Dec 19	26	-27	13	8
30 Sep 19	26	-29	11	10
30 Jun 19	26	-13	9	12
31 Mar 19	27	-11	9	15
31 Dec 18	26	-8	9	15
30 Sep 18	25	-3	9	13
30 Jun 18	24	-12	9	9
31 Mar 18	20	-9	9	5
31 Dec 17	17	-13	8	3
30 Sep 17	14	-12	8	3
30 Jun 17	13	-11	7	3
31 Mar 17	11	-11	7	2
31 Dec 16	12	-12	8	2
30 Sep 16	12	-12	8	2
30 Jun 16	11	-12	8	2
31 Mar 16	11	-10	8	2
31 Dec 15	9	-11	9	2
30 Sep 15	6	-14	11	1
30 Jun 15	3	-14	12	1
31 Mar 15	1	-14	12	1
31 Dec 14	1	-16	9	1
30 Sep 14	8	-18	6	1
30 Jun 14	8	-30	4	1
31 Mar 14	8	-29	4	1
31 Dec 13	7	-26	4	1
30 Sep 13	0	-23	4	1
30 Jun 13	0	-8	3	1

Ingresos de calidad: XXII actualmente no es rentable.

Margen de beneficios creciente: XXII actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: XXII no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 38.8% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de XXII en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: XXII no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Tobacco (0.6%).

Rentabilidad financiera

Alta ROE: El pasivo de XXII supera su activo, por lo que es difícil calcular su rentabilidad financiera.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

22nd Century Group Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings released: US$3.12 loss per share (vs US$4.65 loss in FY 2022)

22nd Century Group, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

22nd Century Group, Inc. to Report Q2, 2023 Results on Aug 14, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

22nd Century Group, Inc. announced that it has received $4.2 million in funding

22nd Century Group, Inc. has filed a Follow-on Equity Offering in the amount of $4.237199 million.

22nd Century Group Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Nasdaq's Listing Rule 5550(b)(1)

Market Participants Recognise 22nd Century Group, Inc.'s (NASDAQ:XXII) Revenues Pushing Shares 1,233% Higher

New major risk - Share price stability

No longer forecast to breakeven

Full year 2023 earnings released: US$3.12 loss per share (vs US$4.65 loss in FY 2022)

22nd Century Group, Inc. to Report Q4, 2023 Results on Mar 28, 2024

22Nd Century Group, Inc. Announces Termination of Peter Ferola as the Chief Legal Officer and Corporate Secretary

High number of new directors

22Nd Century Group, Inc. Appoints Lawrence (Larry) Firestone as Chief Executive Officer

Specialty Acquisition Corporation entered into a equity purchase agreement to acquire Substantially all of GVB hemp/cannabis business from 22nd Century Group, Inc. (NasdaqCM:XXII) and ESI Holdings, LLC for $2.3 million.

Consensus EPS estimates fall by 67%

New major risk - Market cap size

22nd Century Group Receives Non-Compliance Letter from Nasdaq

22nd Century Group, Inc. Continues VLN Expansion, Now Retailing in More Than 5,100 Stores

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Shareholder dilution

22Nd Century Group, Inc. Adds 1,200 Drug Store Locations Selling VLN in Five States

Consensus revenue estimates fall by 11%

Time To Worry? Analysts Just Downgraded Their 22nd Century Group, Inc. (NASDAQ:XXII) Outlook

Price target decreased by 27% to US$31.19

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

22nd Century Group, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Pomerantz LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of 22nd Century Group, Inc. Common Stock

High number of new directors

22Nd Century Group, Inc. Announces Chief Executive Officer Changes

22nd Century Group Regains Compliance with Nasdaq Listing Standards

22Nd Century Group, Inc. Announces Its Vln(R) Reduced Nicotine Content C-Stores

New minor risk - Share price stability

22nd Century Announces 1-For-15 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

22nd Century Group, Inc. Announces Production of VLN(R) Homogenized Tobacco Leaf Sheet

22nd Century Group, Inc. Announces VLN(R) Products Launch in Nevada to Help Smokers Smoke Less

With 22nd Century Group, Inc. (NASDAQ:XXII) It Looks Like You'll Get What You Pay For

22Nd Century Group, Inc. Launches Vln At #1 U.S. C-Store Chain in Texas, California and Florida

Consensus revenue estimates increase by 10%, EPS downgraded

22nd Century Group, Inc. Provides Revenue Guidance for the Full Year 2023

Price target decreased by 11% to US$4.00

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

22nd Century Group, Inc. to Report Q1, 2023 Results on May 09, 2023

Consensus EPS estimates fall by 16%

Full year 2022 earnings: EPS and revenues miss analyst expectations

22nd Century Group, Inc. (NasdaqCM:XXII) acquired Rx Pharmatech Ltd for $0.65 million.

Does 22nd Century Group (NASDAQ:XXII) Have A Healthy Balance Sheet?

Forecast to breakeven in 2025

Key Executive notifies of intention to sell stock

22Nd Century Group, Inc. Appoints John J. Miller as an Executive Officer and President of Tobacco

High number of new directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new directors

22nd Century Group, Inc. to Report Q3, 2022 Results on Nov 08, 2022

22nd Century adds Creager as distribution partner for its VLN cigarettes in Colorado

High number of new directors

22Nd Century Group Appoints Lucille S. Salhany to Its Board

22Nd Century Group, Inc. Announces Executive Changes

22nd Century Group to expand sales of VLN tobacco cigarettes

22nd Century Group (NASDAQ:XXII) Has Debt But No Earnings; Should You Worry?

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

22nd Century GAAP EPS of -$0.06 in-line, revenue of $14.5M beats by $3.21M

Consensus forecasts updated

22nd Century Group, Inc. announced that it has received $35.000009 million in funding

22nd Century Group, Inc. to Report Q2, 2022 Results on Aug 09, 2022

22nd Century Group launches $35M securities offering

22Nd Century Group, Inc. Announces the Appointment of R. Hugh Kinsman as Its Chief Financial Officer

22nd Century Group, Inc. announced that it has received funding

22nd Century Group Announces John J. Miller Joins Its Tobacco Business

Key Executive exercised options to buy US$179k worth of stock.

22nd Century Group, Inc. (NasdaqCM:XXII) acquired GVB BioPharma for $51.7 million.

Desglose de ingresos y gastos
Beta